Marshall Wace North America’s AtriCure ATRC Stock Holding History

Marshall Wace North America’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-98,531	Closed	-$5.49M	–	1492
2020 Q4	$5.49M	Buy	+98,531	New	+$4.26M	0.02%	519
2018 Q3	–	Sell	-135,223	Closed	-$3.66M	–	921
2018 Q2	$3.66M	Buy	135,223 +99,493	+278%	+$2.34M	0.02%	594
2018 Q1	$733K	Buy	+35,730	New	+$645K	﹤0.01%	1069
2017 Q4	–	Sell	-32,728	Closed	-$720K	–	1363
2017 Q3	$720K	Sell	32,728 -13,919	-30%	-$315K	﹤0.01%	1008
2017 Q2	$1.12M	Buy	+46,647	New	+$992K	0.01%	913

Other funds holding ATRC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marshall Wace North America's ATRC Position: Q1 2021 in Review

Marshall Wace North America sold out of AtriCure (ATRC) in Q1 2021, closing a stake of 98,531 shares — an estimated $5.49M sold.

Marshall Wace North America first reported a position in ATRC in Q2 2017 and held it in 5 quarters. The position peaked at $5.49M in Q4 2020. 191 funds tracked by Wall St. Rank hold ATRC as of Q1 2021.

Marshall Wace North America reported no remaining AtriCure position as of Q1 2021 after selling out during the quarter.
Marshall Wace North America sold 98,531 AtriCure shares in Q1 2021, an estimated $5.49M.
Marshall Wace North America first reported a position in AtriCure in Q2 2017 and held it in 5 quarters.
Marshall Wace North America's AtriCure position peaked at $5.49M in Q4 2020.
191 funds tracked by Wall St. Rank held AtriCure as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.